Far from being inert scaffolding, bones are metabolically active tissues that continuously communicate with the brain, immune system, and metabolism to regulate overall health. Recent research reveals that the skeleton functions as an endocrine organ, secreting hormones and signalling molecules that influence blood sugar control, bone density, and immune function—relationships that challenge the traditional view of bones as merely structural support.
Key takeaways
- Bones are living tissues that constantly remodel themselves, breaking down old bone and forming new bone throughout life
- The skeleton secretes osteocalcin and other hormones that regulate blood glucose, energy metabolism, and immune responses
- Bone-derived signals influence brain function, cardiovascular health, and systemic inflammation
- Understanding bone as an endocrine organ has implications for treating metabolic disease, diabetes, and osteoporosis
🟠 Moderate Evidence
Bone’s Endocrine Functions: Multi-System Communication
Key hormones and signalling molecules secreted by bone tissue and their target organs
Source: Contemporary bone physiology research | Georgian Medical Journal News
Bone as a Dynamic Endocrine Organ
Bones are not static structures but rather living tissues engaged in continuous renovation. Adult humans replace approximately 10% of their skeletal mass each year through a process called bone remodelling, in which osteoclasts break down existing bone and osteoblasts form new bone. This ongoing remodelling serves not only to maintain structural integrity but also to allow bones to sense and respond to systemic metabolic demands.
The skeleton’s endocrine function centres on osteocalcin, a protein hormone produced by bone-forming osteoblasts. Research published in peer-reviewed journals on bone biology has demonstrated that osteocalcin circulates in the bloodstream and acts on distant tissues, particularly pancreatic beta cells, where it enhances insulin secretion and improves glucose tolerance. This discovery, emerging from studies in the 2000s, fundamentally repositioned bone from a passive calcium storage site to an active regulator of metabolic homeostasis. Mice engineered to lack osteocalcin develop insulin resistance and glucose intolerance, highlighting the hormone’s metabolic necessity.
Bone-Immune System Crosstalk
Beyond metabolism, bone tissue maintains bidirectional communication with the immune system. The bone marrow houses haematopoietic stem cells that differentiate into blood cells, including lymphocytes and macrophages central to immune defence. Conversely, immune cells regulate bone remodelling through secretion of cytokines such as TNF-α, IL-6, and RANKL (receptor activator of nuclear factor kappa-B ligand), which stimulate osteoclast activity and bone resorption.
During systemic infection or inflammatory states, bone-derived immune cells mobilize from the marrow, and bone resorption increases—a response that provides mineral and metabolic substrates for mounting an immune response. Research examining this axis suggests that chronic low-grade inflammation accelerates bone loss in ageing populations, partly through immune-mediated increases in osteoclast activity. Understanding this crosstalk has opened new therapeutic avenues for conditions such as rheumatoid arthritis, where dysregulated bone-immune interactions drive both joint damage and systemic inflammation.
The skeleton secretes multiple endocrine factors that regulate blood glucose, energy metabolism, and immune function—transforming our understanding of bone from a structural support to a central endocrine and metabolic organ.
— Contemporary bone physiology and endocrinology research consensus
Brain Function and Skeletal Signalling
Emerging evidence suggests that bone-derived molecules also influence central nervous system function and behaviour. Osteocalcin crosses the blood-brain barrier and binds receptors in the hippocampus and hypothalamus, regions critical for memory, mood, and appetite regulation. Animal studies indicate that osteocalcin modulates cognitive performance and anxiety-like behaviour, though human clinical evidence remains limited. This axis raises intriguing questions about whether bone health influences psychiatric and neurodegenerative disease risk.
Additionally, bone secretes other factors including P1NP (procollagen type I N-terminal propeptide) and osteoid-derived peptides that may influence vascular function and inflammation. The full repertoire of bone-derived signalling molecules and their systemic effects remain incompletely mapped, representing an active frontier in endocrinology and systems physiology research.
What this means
Frequently asked questions
How do bones produce hormones if they are solid structures?
Bones contain living cells embedded within the mineral matrix. Osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells) actively secrete hormones and signalling molecules into the bloodstream. The bone marrow, housed within the bone cavity, is particularly rich in cell types that produce immune and metabolic factors. Despite appearing solid to the naked eye, bone tissue is highly vascularized and metabolically active.
What happens if bone signalling fails?
Disrupted bone-derived signalling contributes to multiple pathologies. Mice or humans lacking functional osteocalcin develop insulin resistance and impaired glucose tolerance, increasing diabetes risk. Loss of bone-immune crosstalk underlies the increased infection susceptibility and autoimmune disease risk in conditions causing severe osteoporosis. Conversely, enhanced bone loss during chronic inflammation reflects dysregulated immune-mediated osteoclast activation. Early recognition and treatment of bone disease may prevent downstream metabolic and immunological complications.
Can bone-targeted therapies treat metabolic disease?
This remains an active research question. Traditional osteoporosis medications such as bisphosphonates inhibit osteoclast-mediated bone resorption and are being studied for metabolic benefits in observational cohorts. Emerging therapies targeting the Wnt/β-catenin pathway and sclerostin inhibition aim to stimulate osteoblast activity and new bone formation; whether these approaches improve glucose control or metabolic outcomes in humans requires large randomized trials. Current evidence supports bone health as part of comprehensive metabolic disease prevention but not as monotherapy.
As the field of bone endocrinology matures, the view of the skeleton as merely a static scaffold has given way to recognition of bone as a sophisticated, communicating organ system. Future research will likely identify additional bone-derived factors and clarify their roles in diseases spanning endocrinology, immunology, and neurology. For now, the evidence underscores the interconnectedness of bodily systems and reinforces the importance of bone health across the lifespan—not merely for skeletal integrity but for systemic metabolic and immune resilience. Read more about clinical updates on musculoskeletal health and patient guidance on bone health.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
